Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Adv Protein Chem Struct Biol ; 140: 419-492, 2024.
Article de Anglais | MEDLINE | ID: mdl-38762277

RÉSUMÉ

Discovering a therapeutic that can counteract the aggressiveness of this disease's mechanism is crucial for improving survival rates for cancer patients and for better understanding the most different types of cancer. In recent years, using these viruses as an anticancer therapy has been thought to be successful. They mostly work by directly destroying cancer cells, activating the immune system to fight cancer, and expressing exogenous effector genes. For the treatment of tumors, oncolytic viruses (OVs), which can be modified to reproduce only in tumor tissues and lyse them while preserving the healthy non-neoplastic host cells and reinstating antitumor immunity which present a novel immunotherapeutic strategy. OVs can exist naturally or be created in a lab by altering existing viruses. These changes heralded the beginning of a new era of less harmful virus-based cancer therapy. We discuss three different types of oncolytic viruses that have already received regulatory approval to treat cancer as well as clinical research using oncolytic adenoviruses. The primary therapeutic applications, mechanism of action of oncolytic virus updates, future views of this therapy will be covered in this chapter.


Sujet(s)
Immunothérapie , Tumeurs , Thérapie virale de cancers , Virus oncolytiques , Humains , Virus oncolytiques/immunologie , Virus oncolytiques/génétique , Tumeurs/thérapie , Tumeurs/immunologie , Immunothérapie/méthodes , Thérapie virale de cancers/méthodes , Animaux
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE